Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-ascending-dose study of RO5469754 in healthy adults
NL-OMON37629Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in asthma comparing RO5469754 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2011; status: active, not recruiting.
02
Drugs
RO5469754
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON37629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37629.